trimegestone trimegestone trimegestone, sold under the brand names ondeva and totelle among others, is a progestin medication which is used in menopausal hormone therapy and in the prevention of postmenopausal osteoporosis. it was also under development for use in birth control pills to prevent pregnancy, but ultimately was not marketed for this purpose. the medication is available alone or in combination with an estrogen. it is taken by mouth. trimegestoneclinical datatrade namesginotex, lovelle, minique, ondeva, totelle, othersother namestmg; ru-27987; 21(s)-hydroxypromegestone; 21β-hydroxypromegestone; 21(s)-hydroxy-17α,21-dimethyl-9-dehydro-19-norprogesterone; 21(s)-hydroxy-17α,21-dimethyl-19-norpregna-4,9-dien-3,20-dione; 17β-(s)-lactoyl-17α-methylestra-4,9-dien-3-one; 17β-((s)-2-hydroxypropanoyl)-17α-methylestra-4,9-dien-3-oneroutes ofadministrationby mouthdrug classprogestogen; progestinatc codeg03fa16 (who) legal statuslegal status in general: ℞ (prescription only) pharmacokinetic databioavailability100%protein binding98% (to albumin)metabolismmainly hydroxylationelimination half-liferange: 12–20 hoursmean: 13.8–15.6 hoursidentifiers iupac name (8s,13s,14s,17s)-17--13,17-dimethyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3h-cyclopentaphenanthren-3-one cas number74513-62-5pubchem cid68926drugbankdb13129chemspider62152unii4658k0h08wkeggd06235chebichebi:136027chemblchembl2104765echa infocard100.189.099 chemical and physical dataformulac22h30o3molar mass342.479 g·mol−13d model (jsmol)interactive image smiles c(c(=o)1(cc21(ccc3=c4ccc(=o)c=c4cc23)c)c)o inchi inchi=1s/c22h30o3/c1-13(23)20(25)22(3)11-9-19-18-6-4-14-12-15(24)5-7-16(14)17(18)8-10-21(19,22)2/h12-13,18-19,23h,4-11h2,1-3h3/t13-,18+,19-,21-,22+/m0/s1key:jundjwoldsctfk-mtzclofqsa-n side effects of trimegestone include headache, breast tenderness, nervousness, abdominal pain, bloating, muscle cramps, nausea, depression, and vaginal bleeding among others. trimegestone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. it has weak antiandrogenic and antimineralocorticoid activity and no other important hormonal activity. trimegestone was first described in 1979 and was introduced for medical use in 2001. it is sometimes described as a "fourth-generation" progestin. the medication is marketed throughout europe and latin america. it is not available in the united states or canada. medical uses trimegestone is used in menopausal hormone therapy in the treatment of menopausal symptoms such as hot flashes and vaginal atrophy and in the prevention of postmenopausal osteoporosis. available forms trimegestone is available both alone (as ondeva) and in combination with estradiol (as ginotex, lovelle, minique, totelle), both of which are approved for the treatment of menopausal symptoms and prevention of postmenopausal osteoporosis. preparations of trimegestone are oral tablets and contain 0.1 to 0.5 mg of the medication. side effects